June 22, 2022

UPNEEQ® Wins Best Professional Treatment Product Award by Shape Magazine in 2022 “Shape Healthy Skin Awards”

In the Shape Awards issue, Dr. Elizabeth Halea board-certified dermatologist New York City, refers to the active ingredient in Upneeq as a “trigger” for contraction of an involuntary muscle called Muller’s muscle, to lift the droopy eyelid. “I used it myself and experienced a 1mm lift in my upper eyelid – a subtle but noticeable difference,” the dermatologist said.

“As we continue to grow and make our mark in the field of medical aesthetics, we are thrilled to once again be recognized by an industry leader like Shape Magazine, reaching millions of women focused on the best beauty content, medical treatments and product recommendations as well as an overall healthy lifestyle,” said JD Schaub EVP & Chief Operating Officer. “Another accolade for ‘Best Professional Treatment’ elevates the Upneeq brand and we hope to strengthen the vote of confidence that our hundreds of medical aesthetic practices have in our treatment for this unmet need in the treatment of acquired ptosis.”

Upneeq, Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%, received FDA approval in July 2020, bringing to market the only approved non-surgical treatment for the treatment of acquired blepharoptosis in adults. Upneeq is a first-in-class safe and effective treatment providing patients, eye care and now all medical aesthetic providers upon nationwide rollout in January 2022a simple convenient daily drop.

In clinical trials, Upneeq demonstrated statistically significant improvements over vehicles in upper visual field and eyelid lift, as measured in two pivotal double-blind efficacy and safety studies. For more information and all important safety and prescribing information, visit www.upneeq.com.

IMPORTANT SAFETY INFORMATION

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

WARNINGS AND PRECAUTIONS

  • Ptosis can be associated with neurological or orbital diseases such as stroke and/or cerebral aneurysm, Horner’s syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. These conditions should be considered in the presence of ptosis with decreased levator function and/or other neurological signs.
  • Alpha-adrenergic agonists as a class can impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension and/or uncontrolled hypertension or hypotension to seek medical attention if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical attention if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle-closure glaucoma in patients with untreated angle-closure glaucoma. Advise patients to seek immediate medical attention if signs and symptoms of acute angle-closure glaucoma develop.
  • Patients should not touch the end of the disposable container with their eyes or any surface, in order to avoid eye damage or contamination of the solution.

SIDE EFFECTS

Adverse reactions occurring in 1-5% of UPNEEQ-treated subjects were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache.

DRUGS INTERACTIONS

  • Alpha-adrenergic agonists, as a class, can impact blood pressure. Caution is advised when using medications such as beta-blockers, antihypertensives and/or cardiac glycosides. Caution should also be exercised in patients receiving alpha-adrenergic receptor antagonists, such as in the treatment of cardiovascular disease or benign prostatic hyperplasia.
  • Caution is advised in patients taking monoamine oxidase inhibitors which may affect the metabolism and absorption of circulating amines.

About Shape / Shape Healthy Skin Awards – SHAPE Magazine has been an authoritative voice speaking directly to women who lead active lives, rooted in the scientific expertise of the editors and board of advisors. Through the digital magazine, website, social platforms, and experiences, SHAPE serves as the definitive resource for active wellness, providing information and a trusted roadmap for readers to navigate the path to their health goals. , wellness, fitness, aesthetics and lifestyle. With the SHAPE Healthy Skin Awards, the reader has the confidence, tools, motivation and inspiration to bet every day on looking their best and healthiest with a list of vetted products and procedures presented by an impressive panel of leaders. industry every year.

RVL Pharmaceuticals plc RVL Pharmaceuticals plc (Nasdaq: RVLP) is a specialty pharmaceutical company engaged exclusively in the commercialization of Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Upneeq is the first FDA-approved non-surgical treatment option for the treatment of acquired blepharoptosis, or low eyelid, in adults. For more information or for investor relations, please visit https://www.rvlpharma.com.

Contact with Investor Relations:
Lisa Wilson
Onsite Communications Inc.
[email protected]

Media Contact:
Jill Eisenstadt
[email protected]
310-650-2900

SOURCE INCREASE